查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1424371

吸入剂的全球市场：按药物类别、按产品类型、按应用、按分销管道、按地区

Global Inhalable Drugs Market, By Drug Class (Inhaled Corticosteroids, Leukotriene modifiers, Long-acting beta agonists, Long-acting muscarinic antagonists, Others), By Product Type, By Application, By Distribution Channel, By Region
出版日期: | 出版商: Coherent Market Insights | 英文 206 Pages | 商品交期: 2-3个工作天内

价格
简介目录

全球吸入器市场规模预计将从 2023 年的 348.6 亿美元增至 2030 年的 566.8 亿美元，预测期内复合年增长率为 7.2%。

报告范围 报告详情
基准年 2022年 2023/2024年市场规模 348.6亿美元
实际资料 2018-2021 预测期 2023-2030
2023/2024-2030/2031预测期复合年增长率 7.20% 2030/2031价值预测 566.8亿美元
图 1. 2023 年按地区分類的吸入剂全球市场占有率(%)
全球吸入药物市场-IMG1

吸入药物是经由肺部经呼吸道局部给药时发挥快速治疗效果的医疗物质。它对治疗气喘、慢性阻塞性肺病和囊肿纤维化肺部疾病特别有效。与透过胃肠道口服给药相比，肺部为药物吸收提供了巨大的表面积。吸入药物绕过肝臟首过代谢，允许药物直接快速输送至肺组织并降低全身水平。与口服药物相比，主要优点包括几分钟内快速起效、剂量更低、副作用更少。流行的吸入药物包括治疗气喘和慢性阻塞性肺病的支气管扩张剂，如沙丁胺醇、皮质类固醇、分散抗生素和胰岛素。随着全球肺部疾病的增加，吸入药品市场预计将继续稳定成长。

市场动态：.

全球吸入药物市场受到气喘和慢性阻塞性肺病等呼吸系统疾病全球盛行率不断上升的推动。例如，2023年 3月16日，据世界卫生组织（WHO）称，慢性阻塞性肺病（COPD）是全球第三大死因，2021年将有超过3亿人患有气喘。CD. COPD 每年导致超过 300万人死亡。污染水平的增加和生活方式的改变导致肺部疾病病例数量的增加。该市场也受惠于吸入药物在治疗直接影响呼吸道疾病方面的卓越疗效。定量吸入器 (MDI) 和干粉吸入器 (DPI) 等给药装置的技术进步正在扩大新疗法的机会。然而，与吸入药物的开发和生产相关的高成本限制了更广泛市场的成长。此外，有关肺部给药系统的临床试验和产品核可的严格规定也是一个限制。然而，先进製剂和联合治疗的持续研究和开发可能会在预测期内开闢新的途径。

本研究的主要特点

  • 该报告对全球吸入药物市场进行了详细分析，并提供了以2022年为基准年的预测期（2023-2030）的市场规模和年复合成长率（CAGR%）。
  • 它还阐明了各个细分市场的潜在商机，并解释了该市场有吸引力的投资提案矩阵。
  • 它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
  • 它根据公司亮点、产品系列、主要亮点、财务表现和策略等参数，介绍了全球吸入药物市场的主要企业。
  • 该报告的见解使行销人员和经营团队负责人就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
  • 全球吸入药物市场报告迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
  • 相关人员可以透过分析全球吸入药物市场时所使用的各种策略矩阵来促进决策。

目录

第一章 研究目的与前提

  • 研究目标
  • 先决条件
  • 简称

第二章 市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第三章市场动态、法规及趋势分析

  • 市场动态
  • 监管场景
  • PEST分析
  • 波特的分析
  • 合併、收购和合作

第四章全球吸入药物市场 -冠状病毒(COVID-19) 大流行的影响

  • 新型冠状病毒感染疾病（COVID-19）的流行病学
  • 供需面分析
  • 经济影响

第五章全球吸入药物市场，依药物类别，2018-2030

  • 介绍
  • 吸入性皮质类固醇
  • 白三烯调节剂
  • 长效β拮抗（LABA）
  • 长效毒蕈碱拮抗（LAMA）
  • 其他的

第六章全球吸入药物市场，依产品类型，2018-2030

  • 介绍
  • 气雾剂
  • 干粉配方
  • 注射
  • 其他的

第七章全球吸入药物市场，依应用分类，2018-2030

  • 介绍
  • 呼吸系统疾病
  • 气喘
  • 慢性阻塞性肺病（COPD）
  • 囊肿纤维化
  • 过敏性鼻炎
  • 其他的
  • 非呼吸系统疾病

第8章全球吸入药物市场，按分销管道，2018-2030

  • 介绍
  • 医院药房
  • 零售药房
  • 网路药房

第九章全球吸入药物市场，按地区，2018-2030

  • 介绍
  • 北美洲
  • 美国
  • 加拿大
  • 欧洲
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 欧洲其他地区
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 东南亚国协
  • 其他亚太地区
  • 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东地区
  • 非洲
  • 北非
  • 中部非洲
  • 南非

第10章竞争形势

  • 公司简介
    • GSK plc.
    • Mundipharma International.
    • Boehringer Ingelheim International GmbH.
    • Cipla Inc.
    • AstraZeneca
    • Sanofi
    • Vectura Group Ltd.
    • Viatris Inc.
    • 3M Health Care
    • Allied Healthcare Products, Inc.
    • CareFusion Corporation
    • GF Health Products, Inc.
    • Merck &Co., Inc.
    • Novartis AG
    • Omron Healthcare, Inc.
    • Glenmark Pharmaceuticals
    • PARI Respiratory Equipment, Inc.

第11章 章节

  • 参考
  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI6512

Global inhalable drugs market size is expected to reach US$ 56.68 Bn by 2030, from US$ 34.86 Bn in 2023, exhibiting a CAGR of 7.2% during the forecast period.

Report Coverage Report Details
Base Year: 2022 Market Size in 2023/2024: US$ 34.86 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023/2024 to 2030/2031 CAGR: 7.20% 2030/2031 Value Projection: US$ 56.68 Bn
Figure 1. Global Inhalable Drugs Market Share (%), By Region, 2023
Global Inhalable Drugs Market - IMG1

Inhalable drugs are medical substances that can be administered locally through the respiratory tract via the lung for rapid therapeutic effects. They are particularly effective for treating lung conditions such as asthma, chronic obstructive pulmonary disease and cystic fibrosis. The lung provides huge surface area for drug absorption as compared to oral administration through the gastrointestinal tract. Inhalable drugs bypass hepatic first-pass metabolism for faster delivery of medications directly to the lung tissues and lower systemic levels. Some key advantages include rapid onset of action within minutes, lower dosing, and reduced side effects as compared to oral medications. Popular inhalable drugs include bronchodilators for asthma and chronic obstructive pulmonary disease like albuterol, corticosteroids, dispersible antibiotics, and insulin. With rising lung diseases globally, the inhalable drugs market is expected to grow steadily in the future.

Market Dynamics:

Global inhalable drugs market is driven by the growing prevalence of respiratory diseases such as asthma and COPD worldwide. For instance, on March 16, 2023, according to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, and over 300 Mn people suffered from asthma in 2021, while over 3 Mn people die each year from COPD. Increasing pollution levels and changing lifestyles have contributed to the rising caseload of lung illnesses. The market also benefits from the superior therapeutic efficacy of inhalable drugs in treating conditions, affecting the respiratory tract directly. Technological advancements in drug delivery devices such as metered-dose inhalers (MDIs) and dry powder inhalers (DPIs) are expanding opportunities for novel therapies. However, high costs that are associated with development and production of inhalable drugs limit wider market growth. Additional constraints include stringent regulations around clinical trials and product approval for pulmonary drug delivery systems. Nevertheless, ongoing research and development (R&D) into advanced formulations and combination therapies could unlock new avenues over the forecast period.

Key features of the study:

  • This report provides in-depth analysis of the global inhalable drugs market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global inhalable drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include GSK plc, Mundipharma International., Boehringer Ingelheim International GmbH., Cipla Inc., AstraZeneca, Sanofi, Vectura Group Ltd, Viatris Inc, 3M Health Care, Allied Healthcare Products, Inc., CareFusion Corporation, GF Health Products, Inc., Merck & Co., Inc., Novartis AG, Omron Healthcare, Inc., Glenmark Pharmaceuticals and PARI Respiratory Equipment, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global inhalable drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global inhalable drugs market

Detailed Segmentation:

  • Global Inhalable Drugs Market, By Drug Class
    • Inhaled Corticosteroids
    • Leukotriene modifiers
    • Long-acting beta agonists (LABAs)
    • Long-acting muscarinic antagonists (LAMAs)
    • Others
  • Global Inhalable Drugs Market, By Product Type
    • Aerosol
    • Dry powder Formulation
    • Spray
    • Others
  • Global Inhalable Drugs Market, By Application
    • Respiratory Diseases
    • Asthma
    • Chronic Obstructive Pulmonary Disease (COPD)
    • Cystic Fibrosis
    • Allergic Rhinitis
    • Others
    • Non-respiratory Disease
  • Global Inhalable Drugs Market, By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Inhalable Drugs Market, By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa
  • Top Companies in the Global Inhalable Drugs Market:
    • GSK plc.
    • Mundipharma International.
    • Boehringer Ingelheim International GmbH.
    • Cipla Inc.
    • AstraZeneca
    • Sanofi
    • Vectura Group Ltd.
    • Viatris Inc.
    • 3M Health Care
    • Allied Healthcare Products, Inc.
    • CareFusion Corporation
    • GF Health Products, Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Omron Healthcare, Inc.
    • Glenmark Pharmaceuticals
    • PARI Respiratory Equipment, Inc.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Inhalable Drugs Market, By Drug Class
    • Global Inhalable Drugs Market, By Product Type
    • Global Inhalable Drugs Market, By Application
    • Global Inhalable Drugs Market, By Distribution Channel
    • Global Inhalable Drugs Market, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Growing prevalence of respiratory diseases
    • Risk of misuse of inhalable medicines
    • Emergence of new drug delivery technologies
  • Key Highlights
  • Regulatory Scenario
  • Recent Trends
  • PEST Analysis
  • PORTER's Analysis
  • Mergers, Acquisitions, and Collaborations

4. Global Inhalable Drugs Market- Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Inhalable Drugs Market, By Drug Class, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Inhaled Corticosteroids
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Leukotriene modifiers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Long-acting beta antagonists (LABAs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Long-acting muscarinic antagonists (LAMAs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

6. Global Inhalable Drugs Market, By Product Type, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Aerosol
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Dry powder Formulation
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Spray
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

7. Global Inhalable Drugs Market, By Application, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Respiratory Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Cystic Fibrosis
  • Allergic Rhinitis
  • Others
  • Non-respiratory Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

8. Global Inhalable Drugs Market, By Distribution Channel, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

9. Global Inhalable Drugs Market, By Region, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Region, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Region, 2019 -2030
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030,(US$ Bn)
  • North Africa
  • Central Africa
  • South Africa

10. Competitive Landscape

  • Company Profile
    • GSK plc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Mundipharma International.
    • Boehringer Ingelheim International GmbH.
    • Cipla Inc.
    • AstraZeneca
    • Sanofi
    • Vectura Group Ltd.
    • Viatris Inc.
    • 3M Health Care
    • Allied Healthcare Products, Inc.
    • CareFusion Corporation
    • GF Health Products, Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Omron Healthcare, Inc.
    • Glenmark Pharmaceuticals
    • PARI Respiratory Equipment, Inc.
  • Analyst Views

11. Section

  • Reference
  • Research Methodology
  • About us